Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 13,471 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endocrine Disorders Clear all
Completed Phase 1Phase 2 Interventional Results available

Phlebotomy Study of Testosterone Undecanoate

NCT02670343
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 3 Interventional

Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas

NCT00003049
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, leucovorin calcium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Nov 10, 2026, 6:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

22 G - 25 G SINS Trial for Pancreatic Masses

NCT02424838
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
EUS-FNA of pancreatic masses, 22 gauge needle, 25 gauge needle
Procedure · Device
Lead sponsor
AdventHealth
Other
Eligibility
19 Years to 89 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 3 Interventional

Open-Label Study of ARD-0403 in Testosterone Deficient Men

NCT00448955
View directory record Official record
Conditions
Hypogonadism
Interventions
ARD-0403
Drug
Lead sponsor
Ardana Bioscience Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Stanford, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2008 · Synced Nov 10, 2026, 6:57 PM EST
Terminated Phase 4 Interventional Results available

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

NCT02912455
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
canagliflozin, Placebo (for canagliflozin)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Nov 10, 2026, 6:57 PM EST
Not yet recruiting Phase 2 Interventional

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

NCT07743138
View directory record Official record
Conditions
Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 1 Interventional

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

NCT01908478
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Veliparib, Gemcitabine, Intensity modulated radiation therapy
Drug · Radiation
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Nov 10, 2026, 6:57 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Adaptive Optics for Ophthalmic Technologies

NCT02826655
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
WF-AO-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Nov 10, 2026, 6:57 PM EST
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Nov 10, 2026, 6:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes

NCT00726778
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Years to 12 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

NCT01068743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Nov 10, 2026, 6:57 PM EST
Terminated Phase 4 Interventional Results available

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

NCT00799435
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Interventions
Exenatide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 1Phase 2 Interventional

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

NCT00051948
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
TLK286
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Santa Monica, California • Skokie, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 1 Interventional

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

NCT02646748
View directory record Official record
Conditions
Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer)
Interventions
Pembrolizumab, itacitinib, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 4 Interventional Results available

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

NCT01226043
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Nov 10, 2026, 6:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Nov 10, 2026, 6:57 PM EST
Completed Not applicable Interventional Results available

MedStar Health Type 2 Diabetes Pathway to Control

NCT02925312
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Diabetes Pathway
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Nov 10, 2026, 6:57 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Effect of PARP Inhibitors on Glomerular Filtration Rate

NCT04367467
View directory record Official record
Conditions
Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions
Kidney Function Test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 2 Interventional

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

NCT00085371
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
triapine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Nov 10, 2026, 6:57 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics

NCT01411930
View directory record Official record
Conditions
Diabetes
Interventions
Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Nov 10, 2026, 6:57 PM EST
Completed Not applicable Interventional

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

NCT01072565
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SMBG to guide clinical decisions, SMBG and CGM
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Nov 10, 2026, 6:57 PM EST
Completed No phase listed Observational

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

NCT00433628
View directory record Official record
Conditions
HIV, Diabetes, Hyperglycemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 10, 2026, 6:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation

NCT05404711
View directory record Official record
Conditions
Overweight and Obesity, PreDiabetes, Insulin Resistance
Interventions
CGM
Device
Lead sponsor
Mary Ellen Vajravelu, MD
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Nov 10, 2026, 6:57 PM EST
Active, not recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
eneboparatide, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Nov 10, 2026, 6:57 PM EST